Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

The company disclosed preliminary results in mid January, but it left out important metrics such as earnings per share for the fourth quarter.

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Eli Lilly will announce Q4 2024 results, with analysts estimating $13.7 billion in sales and $4.94 EPS, alongside a revenue growth outlook for 2024.

Eli Lilly (NYSE:LLY) is scheduled to announce Q4 earnings results on Thursday, February 6th, before market open. The ...

Tirzepatide is FDA-approved for weight loss as the brand-name drug Zepbound. It is also FDA-approved for type 2 diabetes management as the brand-name drug Mounjaro. Doctors can prescribe Mounjaro ...

To learn more, you can refer to this Mounjaro for weight loss article. Note: The FDA has recently approved Zepbound to help with weight loss in certain people. Zepbound is a new prescription ...